IMAN HANNA: Open Payments
NPI 1831247766 · UPLAND, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$383 in 12 payments from 7 companies in 2025. Trend: 2023 $429 · 2024 $511 · 2025 $383
Food & beverage: $383
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $104 |
| Penumbra, Inc. | 1 | $101 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $89 |
| Neurocrine BioSciences, Inc. | 1 | $29 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| ABBVIE INC. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
Products named: Penumbra System, CAPLYTA, REXULTI, INGREZZA, Auvelity, VRAYLAR, Qelbree, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
